Introduction
============

Breast cancer (BC) is the most common female malignancy and the second leading cause of mortality in women worldwide ([@b1-ijmm-44-02-0390]). According to the World Health Organization in 2012, one-third of Asian women develop BC ([@b2-ijmm-44-02-0390],[@b3-ijmm-44-02-0390]). Currently, BC treatment includes partial excision with or without radiotherapy and systemic therapies such as endocrine therapy, chemotherapy, molecular targeted therapy, and a combination of them ([@b4-ijmm-44-02-0390]). Although advanced therapeutic techniques based on surgery have considerably improved the survival of patients with BC and the five-year survival has increased from 75% in 1976 to 91% in 2017, high rates of metastasis and recurrence remain ([@b1-ijmm-44-02-0390],[@b5-ijmm-44-02-0390],[@b6-ijmm-44-02-0390]). Recently, molecular targeted therapy has been shown to play an important role in individualized treatment of BC. For instance, a monoclonal antibody against HER2, trastuzumab, has been demonstrated to improve survival of patients with BC; however, the prognosis remains poor ([@b7-ijmm-44-02-0390],[@b8-ijmm-44-02-0390]). Therefore, to improve BC prognosis, effective therapeutic targets and prognostic biomarkers are needed.

NDC80 kinetochore complex component (*NUF2*), also known as CDCA1, is a centromere-related protein ([@b9-ijmm-44-02-0390]). It regulates the binding of centromeres to spindle microtubules, participates in cell cycle regulation and has important roles in cell proliferation and apoptosis ([@b10-ijmm-44-02-0390]). *NUF2* is overexpressed in a number of cancers, including lung cancer, cholangiocarcinoma, renal cell carcinoma and bladder cancer ([@b11-ijmm-44-02-0390]). Although the expression and prognostic significance of *NUF2* in BC have been suggested ([@b12-ijmm-44-02-0390],[@b13-ijmm-44-02-0390]), its precise role and underlying molecular mechanisms of action remain to be investigated.

In the present study, 4 mRNA microarray datasets were analyzed from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases to identify differentially expressed genes (DEGs) between BC tissues and normal breast tissues. The bioinformatics analysis and literature mining suggested that *NUF2* is a key gene in the progression of BC. The expression of *NUF2* in BC samples and its correlation with clinical pathological characteristics were then analyzed. In addition, the prognostic value of *NUF2* was analyzed using individual and pooled methods. In a gene set enrichment analysis (GSEA), it was demonstrated that *NUF2* might be involved in cell-cycle related pathways. The results of the present study suggest that *NUF2* is a prognostic indicator of BC.

Materials and methods
=====================

Microarray data
---------------

GSE42568 ([@b14-ijmm-44-02-0390]), GSE45827 ([@b15-ijmm-44-02-0390]), GSE65194 ([@b16-ijmm-44-02-0390]) and TCGA BC microarray datasets, downloaded from GEO ([@b17-ijmm-44-02-0390]) and TCGA ([@b18-ijmm-44-02-0390]), were used to screen DEGs in BC. The TCGA dataset was used for analyses of clinical pathological characteristics associated with *NUF2* in patients with BC. The following 5 additional BC microarray datasets were selected for prognostic analyses: GSE1456 ([@b19-ijmm-44-02-0390]), GSE22220 ([@b20-ijmm-44-02-0390]), NKI ([@b21-ijmm-44-02-0390]), GSE4299 ([@b22-ijmm-44-02-0390]) and GSE20685 ([@b23-ijmm-44-02-0390]). To normalize mRNA levels, patients for each dataset were reclassified into four subsets (X1, X2, X3 and X4) based on the quartile for expression values. The datasets were then reclassified into a new dataset for a pooled analysis.

DEG identification
------------------

BC-related microarray data downloaded from the GEO and TCGA databases were processed using R software (version 3.4.3; <https://cran.r-project.org/>). DEGs between BC tissues and normal breast tissues were identified using the limma package in R. Fold-change (FC) values were calculated and the DEGs were further selected based on the following cutoff criteria: P\<0.01 and log \|FC\|\>2. Overlapping DEGs among the four datasets were identified using Funrich (version 3.1.3; <http://www.funrich.org>).

Functional and pathway enrichment analyses of DEGs
--------------------------------------------------

Gene Ontology (GO) is used to identify enriched functions of genes in three independent categories: Biological process (BP), molecular function (MF) and cellular component (CC) ([@b24-ijmm-44-02-0390]). Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to identify relevant pathways for the genes ([@b25-ijmm-44-02-0390]). GO BP and KEGG signaling pathway analyses of the DEGs were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID) online tool (<https://david.ncifcrf.gov/>) ([@b26-ijmm-44-02-0390]) with P\<0.05 as the threshold for significance.

Protein-protein interaction (PPI) network analysis
--------------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING; <https://string-db.org/>) was used to develop a PPI network. Using the STRING database, DEGs with a combined score ≥0.4 were chosen to construct the network, which was visualized using Cytoscape (version 3.6.1) ([@b27-ijmm-44-02-0390]). Molecular Complex Detection (MCODE), a plugin for Cytoscape, was used to construct functional modules in the PPI network.

Gene set enrichment analysis (GSEA)
-----------------------------------

A GSEA was conducted based on protocols obtained from the website (<http://software.broadinstitute.org/gsea/index.jsp>) and a previous study ([@b28-ijmm-44-02-0390]). GSEA (version 3.0) was run for the KEGG gene sets (c2.cp.kegg.v.6.0.symbols.gmt). The number of permutations was set to 1,000 and the phenotype labels were *NUF2*-high and *NUF2*-low. FDR \<0.25 and NOM P\<0.05 indicated statistical significance.

Oncomine analysis
-----------------

Oncomine (<https://www.oncomine.org/>) is an online cancer microarray database, aiming to facilitate the discovery of novel biomarkers from genome-wide expression analyses. In the present study, the mRNA expression differences of *NUF2* between BC and normal breast tissues were explored using the Oncomine database.

Patients and samples
--------------------

BC and matched adjacent tissues were collected from the Pathology Department of Shaoxing People\'s Hospital (Shaoxing, China). Samples were obtained from 42 patients at initial diagnosis and were immediately frozen in liquid nitrogen. The present study was authorized by the Hospital Ethics Committee and informed consent was obtained from all patients.

Reverse transcription (RT)-quantitative (q)PCR
----------------------------------------------

Total RNA was isolated from the BC and matched adjacent tissues using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The Nanodrop 2000 (Thermo Fisher Scientific, Inc.) was used to detect the purity and concentration of the total RNA. According to the manufacturer\'s protocol, RT-qPCR was performed using the LightCycler^®^ 480 PCR apparatus (Roche Diagnostics, Basel, Switzerland) and the One Step SYBR^®^ PrimeScript™ RT-PCR kit II (Takara Bio, Inc., Otsu, Japan). Amplification was performed under the following conditions: 42°C for 5 min, 95°C for 10 sec; 40 cycles of 95°C for 5 sec and 60°C for 20 sec; and 65°C for 15 sec. The primers used were as follows: *NUF2* forward primer 5′-TACCATTCAGCAATTTAGTTACT-3′ and reverse primer 5′-TAGAATATCAGCAGTCTCAAAG-3′; and *β-actin* forward primer 5′-CATGTACGTTGCTATCCAGGC-3′ and reverse primer 5′-CTCCTTAATGTCACGCACGAT-3′. The relative levels of *NUF2* expression were evaluated by the 2^−ΔΔCq^ ([@b29-ijmm-44-02-0390]) method using *β-actin* as the control.

Statistical analyses
--------------------

All statistical analyses were performed using SPSS 20.0 (IBM Corps., Armonk, NY, USA). An independent t-test was used for analyzing the continuous data. The χ^2^ test and χ^2^ test with continuity correction were performed to analyze the association of *NUF2* with clinical pathological characteristics. Bonferroni\'s post hoc test was used to analyze the clinical pathological characteristics between more than 2 groups. Survival curves were generated by the Kaplan-Meier method and significance was determined using the log-rank test. Bonferroni\'s post hoc test was used for pairwise comparisons. Multivariable survival analysis was performed using the Cox proportional hazards regression model and significance was determined using the likelihood ratio test. P\<0.05 was considered to indicate statistically significant differences, while for Bonferroni\'s test, P\<0.05/N was considered to indicate statistically significant differences, where N=the number of pairwise comparisons.

Results
=======

Identification of DEGs in BC
----------------------------

DEGs between the BC and normal breast tissues were screened using the GEO and TCGA databases. As shown in [Fig. 1A](#f1-ijmm-44-02-0390){ref-type="fig"}, 1,702, 461, 600 and 337 DEGs were upregulated in the GSE45827, GSE42568, GSE65194, and TCGA datasets, and 613, 715, 264, and 872 DEGs were downregulated, respectively ([Fig. 1B](#f1-ijmm-44-02-0390){ref-type="fig"}). In total, 190 DEGs exhibited the same expression trends in all datasets, including 65 upregulated and 125 downregulated genes.

Functional and pathway enrichment for the DEGs
----------------------------------------------

GO BP and KEGG signaling pathway analyses of the DEGs were performed using DAVID. The upregulated DEGs were mainly enriched for the BP terms cell division, mitotic nuclear division and G2/M transition of mitotic cell cycle ([Fig. 2A](#f2-ijmm-44-02-0390){ref-type="fig"}), while downregulated DEGs were significantly associated with lipid metabolic process, cholesterol homeostasis, and glucose metabolic process ([Fig. 2B](#f2-ijmm-44-02-0390){ref-type="fig"}). Additionally, seven KEGG pathways were identified for the upregulated genes, including the *p53* signaling pathway, cell cycle and extracellular matrix (ECM)-receptor interaction ([Fig. 2C](#f2-ijmm-44-02-0390){ref-type="fig"}). The peroxisome proliferator-activated receptor (PPAR) signaling pathway, AMP-activated protein kinase (AMPK) signaling pathway and proximal tubule bicarbonate reclamation were associated with the downregulated DEGs ([Fig. 2D](#f2-ijmm-44-02-0390){ref-type="fig"}). The detailed results are presented in [Table I](#tI-ijmm-44-02-0390){ref-type="table"}.

PPI network analysis and the selection of NUF2
----------------------------------------------

Protein interactions often play important roles in cancer progression. A PPI network analysis was performed using the STRING database and Cytoscape. The PPI network was constructed using 149 DEGs (57 upregulated and 92 downregulated DEGs) with combined scores ≥0.4, and contained 149 nodes and 930 edges ([Fig. 3A](#f3-ijmm-44-02-0390){ref-type="fig"}). A total of two functional modules were identified using the MCODE plugin. Module 1 consisted of 35 nodes and 573 edges including *NUF2, TOP2A, ASPM,* and *CCNB1* ([Fig. 3B](#f3-ijmm-44-02-0390){ref-type="fig"}). Module 2 included 21 nodes and 104 edges including *COL1A1, MMP1, MMP9,* and *LPL* ([Fig. 3C](#f3-ijmm-44-02-0390){ref-type="fig"}). Based on the degree of importance, module 1 was chosen for further analysis.

The 35 genes in module 1 were ranked based on log \|FC\| values in the TCGA database and selected the top 10 hub genes for further analysis. The expression levels of the 10 hub genes in the BC tissues were \>10-fold (log \|FC\|≥3.42) increased compared with those in the normal breast tissues. Through literature mining, it was identified that *UBE2C, ASPM, BIRC5, TOP2A, KIF20A, CEP55, TPX2, NEK2* and *ANLN*, but not *NUF2*, have been reported extensively in BC-related studies. Therefore, *NUF2* was selected as the focus of subsequent analyses.

NUF2 expression in BC
---------------------

The expression of *NUF2* mRNA in the BC tissues was evaluated using Oncomine (<https://www.oncomine.org/>) ([@b30-ijmm-44-02-0390]). The results indicated that the *NUF2* expression level is significantly increased in the BC tissues compared with in the normal breast tissues (P\<0.01; [Fig. 4A-C](#f4-ijmm-44-02-0390){ref-type="fig"}). To further verify these results, 42 pairs of BC tissues and adjacent tissues were analyzed by RT-qPCR. Consistent with the results of the database analysis, the expression of *NUF2* mRNA in the BC tissues was significantly increased (P\<0.001) compared with in the adjacent tissues ([Fig. 4D](#f4-ijmm-44-02-0390){ref-type="fig"}).

Association of NUF2 with clinical pathological characteristics and survival of patients with BC
-----------------------------------------------------------------------------------------------

To further validate the clinical value of *NUF2*, the association between its expression and the clinical pathological characteristics of the 42 patients with BC recruited from Shaoxing People\'s Hospital were assessed. The expression of *NUF2* was only significantly associated with age (P\<0.05). Using the data in the TCGA database (contains data on 1,090 patients with BC), *NUF2* expression was found to be significantly associated with age (P\<0.001), estrogen receptor (ER) status (P\<0.001), progesterone receptor (PR) status (P\<0.001), histological type (P\<0.001), TNM stage (P\<0.05), and molecular subtype (P\<0.001). The results are shown in [Tables II](#tII-ijmm-44-02-0390){ref-type="table"} and [III](#tIII-ijmm-44-02-0390){ref-type="table"}. Furthermore, the clinical pathological characteristics that have multiple groups (\>2) need a post hoc test to determine exactly what groups exhibit a difference. Therefore, Bonferroni\'s post hoc test was used for pairwise comparison. The results showed that *NUF2* expression is statistically different between TNM stage 1 and 2 (P\<0.01), and tumor stage T1 and T2 (P\<0.001). In terms of molecular subtype, *NUF2* expression was also significantly different in all pairwise comparisons (P\<0.001) except between luminal A and normal-like, and luminal B and basal-like. The detailed results are shown in [Tables IV](#tIV-ijmm-44-02-0390){ref-type="table"} and [V](#tV-ijmm-44-02-0390){ref-type="table"}.

Furthermore, to elucidate the correlation between the expression of *NUF2* and patient survival, 5 GEO datasets were used. Samples from each dataset were reclassified into four subsets (X1, X2, X3 and X4) according to the quartile of *NUF2* expression. The X1 subset was set with the lowest expression as the reference to calculate the hazard ratio (HR). Each dataset was analyzed by Kaplan-Meier analysis and Cox proportional hazard analysis. High *NUF2* expression was associated with shorter overall survival (OS) and progression-free survival (PFS) compared with low *NUF2* expression in the GSE1456 dataset ([Fig. 5A and B](#f5-ijmm-44-02-0390){ref-type="fig"}) and NKI dataset ([Fig. 5C and D](#f5-ijmm-44-02-0390){ref-type="fig"}). Similar results were obtained in the GEO pooled analysis, as shown in [Fig. 5E and F](#f5-ijmm-44-02-0390){ref-type="fig"}. Based on a further GEO pooled analysis, it was demonstrated that *NUF2* expression levels are significantly associated with poor OS and PFS in both ER-positive (P\<0.01; [Fig. 6A and B](#f6-ijmm-44-02-0390){ref-type="fig"}) and ER-negative (P\<0.01; [Fig. 6C and D](#f6-ijmm-44-02-0390){ref-type="fig"}) BC, and the association is more obvious in ER-positive BC. The results of Cox proportional hazards analysis are shown in [Table VII](#tVII-ijmm-44-02-0390){ref-type="table"}. In addition, the results of the Bonferroni\'s post hoc tests used to compare the Kaplan-Meier survival curves corresponding to \>2 groups are shown in [Table VI](#tVI-ijmm-44-02-0390){ref-type="table"}. These results indicated that *NUF2* might be a prognostic factor for BC.

Signaling pathways associated with NUF2
---------------------------------------

Single-gene differential expression analyses in the study of biological processes are limited ([@b28-ijmm-44-02-0390]). To effectively reveal the biological significance of microarray datasets, a GSEA was performed to predict gene sets and signaling pathways associated with *NUF2* using the data obtained from the TCGA database. As shown in [Fig. 7A-C](#f7-ijmm-44-02-0390){ref-type="fig"}, *NUF2* may function in cell cycle-related pathways, including the cell cycle, DNA replication, and *p53* signaling pathway.

Discussion
==========

BC is the most common malignant tumor in women, accounting for 25% of female tumors ([@b3-ijmm-44-02-0390]). Despite advanced treatment techniques, BC remains the leading cause of death among women ([@b31-ijmm-44-02-0390]). Therefore, there is a pressing need for more effective molecular biomarkers to prevent, diagnose, and treat BC. With the development of microarray technology, hundreds of molecules have been found to be abnormally expressed during breast carcinogenesis and progression. The TCGA and GEO databases provide a large number of publicly available microarray datasets for biomarker identification.

In this study, 190 DEGs with the same expression trends were identified in four datasets, and a GO BP analysis showed that the upregulated DEGs were mainly enriched in the biological processes of cell division, mitotic nuclear division, and G2/M transition of mitotic cell cycle, while the downregulated DEGs were related to lipid metabolic process, cholesterol homeostasis, and glucose metabolic process. Cell division and cell cycle are the basic processes in cell proliferation, and their abnormalities contribute to carcinogenesis and tumor progression ([@b32-ijmm-44-02-0390]). Furthermore, the activation of key regulators of lipid and cholesterol metabolism drives the estrogen-independent growth of invasive lobular breast carcinoma cells ([@b33-ijmm-44-02-0390]). A KEGG signaling pathway analysis of the DEGs in this study revealed the importance of the cell cycle, ECM-receptor interaction, PPAR signaling pathway, and AMPK signaling pathway in BC. Previous studies have reported that ECM could regulate tissue homeostasis, and its dysregulation could promote tumor progression by affecting adhesion, migration, differentiation, proliferation, and apoptosis of tumor cells ([@b34-ijmm-44-02-0390],[@b35-ijmm-44-02-0390]). In addition, an increase in the rigidity of the ECM due to the local accumulation of crosslinked collagen matrix is associated with cancer progression ([@b36-ijmm-44-02-0390]). Yao *et al* ([@b37-ijmm-44-02-0390]) found that the PPAR signaling pathway is involved in breast carcinogenesis. Song *et al* ([@b38-ijmm-44-02-0390]) suggested that activation of the AMPK signaling pathway may be beneficial for the promotion of tumor necrosis factor-related apoptosis-inducing ligand-mediated anti-BC treatment. a PPI network was constructed in this study and two functional modules were identified. According to the MCODE scores, which represent importance, module 1 was found to play a major role in the PPI network. By combining the log \|FC\| values of the DEGs in the TCGA database and literature mining, *NUF2* was selected for further research as a key gene in BC.

Although Xiang *et al* ([@b12-ijmm-44-02-0390]) found that *NUF2* is upregulated in BC, using cDNA microarray data of BC patients, further experiments have not been performed to verify this finding. In this study, by Oncomine analysis and RT-qPCR assay, it was verified that *NUF2* is overexpressed in BC tissues, further confirming the results obtained by data mining. Shiraishi *et al* ([@b39-ijmm-44-02-0390]) found that *NUF2* expression is significantly associated with prostate cancer recurrence, and patients with high *NUF2* expression have significantly shorter survival times without biochemical recurrence. Hu *et al* ([@b10-ijmm-44-02-0390]) showed that the overexpression of *NUF2* could be related to poor prognosis in pancreatic cancer. Zhang *et al* ([@b13-ijmm-44-02-0390]) found that *NUF2* expression has prognostic values for BC patients, by simply using the BC-GenExMiner online analysis tool. However, further analysis has not been conducted. To this end, the present study analyzed the precise roles and underlying molecular mechanisms of *NUF2* in BC. By stratified analysis and pooled analysis of five GEO datasets, it was found that patients with BC and high *NUF2* expression had worse prognosis than patients with low *NUF2* expression in both ER-positive and ER-negative BC. Using clinical data for 42 patients, it was demonstrated that *NUF2* expression was only associated with age. Small sample size, erroneous tissue sampling, RNA degradation, and fluctuating efficiency of RT-qPCR may affect the results of the analysis. This hypothesis can be tested through the following methods: Increasing sample size, determining the type of tissue with pathological examination, detecting RNA degradation by RNA electrophoresis, and verifying amplification efficiency of RT-qPCR by the standard curve method. The lack of additional experiments to test these possibilities is a limitation to the present study. Therefore, the relationship was further analyzed using clinical data for patients with BC in the TCGA database. The expression of *NUF2* was positively correlated with tumor stage and negatively correlated with ER status, consistent with the results from a number of studies showing that advanced tumors and ER-negative tumors are probably related to poor survival ([@b40-ijmm-44-02-0390]-[@b42-ijmm-44-02-0390]), suggesting that *NUF2* plays an important role in tumor progression and prognosis. To elucidate the molecular mechanisms by which *NUF2* mediates breast carcinogenesis and progression, GSEA was performed in this study. The results revealed that *NUF2* is involved in cell cycle-related pathways.

In conclusion, the present data analysis and RT-qPCR validation indicated that *NUF2* is highly expressed in BC and is associated with its multiple pathological features and prognosis. *NUF2* is therefore a potential therapeutic target and prognostic indicator of BC. However, this study had several limitations. First, only mRNA data were obtained from the databases and RT-qPCR, and this single-gene-level analysis cannot fully capture the expression of *NUF2* in BC. Second, experimental validation of the results was not performed. Therefore, further research is required to determine the roles of *NUF2* in BC.

*NUF2* is overexpressed in BC and is associated with its multiple pathological features. More importantly, *NUF2* may play an important role in predicting the clinical outcomes of different BC subgroups.
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![Identification of DEGs in breast cancer microarray datasets. In total, (A) 65 DEGs were upregulated and (B) 125 DEGs were downregulated in the intersection of the GSE45827, GSE42568, GSE65194, and TCGA datasets. DEGs, differentially expressed genes; TCGA, the Cancer Genome Atlas.](IJMM-44-02-0390-g00){#f1-ijmm-44-02-0390}

![GO BP analysis and KEGG signaling pathway analysis of DEGs in breast cancer. GO BP analysis of (A) upregulated and (B) downregulated DEGs. KEGG signaling pathway enrichment analysis of (C) upregulated and (D) downregulated DEGs. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto encyclopedia of genes and genomes; ECM, extracellular matrix.](IJMM-44-02-0390-g01){#f2-ijmm-44-02-0390}

![PPI network analysis of DEGs. (A) PPI network containing 149 nodes and 930 edges. (B) Module 1 consisted of 35 nodes and 573 edges, as identified by the MCODE plugin in Cytoscape. (C) Module 2 consisted of 21 nodes and 104 edges, as identified by the MCODE plugin in Cytoscape. Blue nodes represent downregulated genes in BC tissues; red nodes represent upregulated genes in BC tissues. PPI, protein-protein interaction; DEG, differentially expressed genes; BC, breast cancer; MCODE, Molecular Complex Detection.](IJMM-44-02-0390-g02){#f3-ijmm-44-02-0390}

![Expression of *NUF2* in BC. (A) *NUF2* mRNA was overexpressed in human BC tissues compared with normal breast tissues in the TCGA, (B) Curtis and (C) Richardson microarray databases, as evaluated by Oncomine analysis. (D) *NUF2* mRNA expression was increased in most BC lesions compared with para-carcinoma tissues, as determined by reverse transcription-quantitative PCR. ^\*\*\*^P\<0.001. BC, breast cancer; NUF2, NDC80 kinetochore complex component.](IJMM-44-02-0390-g03){#f4-ijmm-44-02-0390}

![Role of *NUF2* in the prognosis of BC patients. (A) *NUF2* expression was significantly associated with OS of BC patients in the GSE1456 dataset, (C) NKI dataset, and (E) GEO pooled dataset. *NUF2* expression was significantly associated with PFS of BC patients in the (B) GSE1456 dataset, (D) NKI dataset and (F) GEO pooled dataset. GEO, gene expression omnibus; BC, breast cancer; OS, overall survival; PFS, progression free survival; ER, estrogen receptor; PR, progesterone receptor; NUF2, NDC80 kinetochore complex component.](IJMM-44-02-0390-g04){#f5-ijmm-44-02-0390}

![Prognostic value of *NUF2* in ER-positive and ER-negative BC. Association of *NUF2* expression with (A) OS and (B) PFS in ER-positive BC in the GEO pooled dataset. Association of *NUF2* expression with (C) OS and (D) PFS in ER-negative BC in the GEO pooled dataset. GEO, gene expression omnibus; BC, breast cancer; OS, overall survival; PFS, progression free survival; ER, estrogen receptor; PR, progesterone receptor; NUF2, NDC80 kinetochore complex component.](IJMM-44-02-0390-g05){#f6-ijmm-44-02-0390}

![Signaling pathways associated with *NDC80 kinetochore complex* component predicted by gene set enrichment analysis. (A) Cell cycle (P=0.000; FDR=0.000; ES=0.72). (B) DNA replication (P\<0.001; FDR\<0.001; ES=0.84). (C) *p53* signaling pathway (P=0.000; FDR=0.004; ES=0.51). FDR, false discovery rate; KEGG, Kyoto Encyclopedia of genes and genomes; ES, enrichment score.](IJMM-44-02-0390-g06){#f7-ijmm-44-02-0390}

###### 

Significantly enriched GO biological process terms and KEGG pathways.

  A, Upregulated                                                                                                          
  ------------------ ---------------------------------------------------------------------------------- ----------------- --------------
  GO Terms                                                                                                                
   GO:0051301        Cell division                                                                      18                1.02×10^−14^
   GO:0007067        Mitotic nuclear division                                                           16                1.90×10^−14^
   GO:0000086        G2/M transition of mitotic cell cycle                                              9                 4.82×10^−08^
   GO:0031145        Anaphase-promoting complex-dependent catabolic process                             7                 5.40×10^−07^
   GO:0042787        Protein ubiquitination involved in Ubiquitin-dependent protein catabolic process   8                 1.83×10^−06^
   GO:0007062        Sister chromatid cohesion                                                          7                 2.58×10^−06^
   GO:0030574        Collagen catabolic process                                                         6                 4.40×10^−06^
   GO:0008283        Cell proliferation                                                                 9                 7.20×10^−05^
   GO:0051439        Regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle     4                 8.86×10^−05^
   GO:0035987        Endodermal cell differentiation                                                    4                 1.45×10^−04^
  KEGG pathways                                                                                                           
   hsa04110          Cell cycle                                                                         8                 1.17×10^−06^
   hsa04512          ECM-receptor interaction                                                           7                 2.33×10^−06^
   hsa04115          p53 signaling pathway                                                              5                 0.000237
   hsa04114          Oocyte meiosis                                                                     5                 0.001499
   hsa04510          Focal adhesion                                                                     5                 0.014347
   hsa04151          PI3K-Akt signaling pathway                                                         6                 0.019962
   hsa05200          Pathways in cancer                                                                 6                 0.032832
  B, Downregulated                                                                                                        
  Terms              Description                                                                        Number of genes   P-value
  GO Terms                                                                                                                
   GO:0006629        Lipid metabolic process                                                            9                 1.32×10^−05^
   GO:0019915        Lipid storage                                                                      5                 2.06×10^−05^
   GO:0048662        Negative regulation of smooth muscle cell proliferation                            5                 4.49×10^−05^
   GO:0042632        Cholesterol homeostasis                                                            6                 7.95×10^−05^
   GO:0008217        Regulation of blood pressure                                                       6                 8.56×10^−05^
   GO:0006006        Glucose metabolic process                                                          6                 9.90×10^−05^
   GO:0019433        Triglyceride catabolic process                                                     4                 6.61×10^−04^
   GO:0042593        Glucose homeostasis                                                                6                 6.74×10^−04^
   GO:0019432        Triglyceride biosynthetic process                                                  4                 7.44×10^−04^
   GO:0001523        Retinoid metabolic process                                                         5                 8.33×10^−04^
  KEGG pathways                                                                                                           
   hsa03320          PPAR signaling pathway                                                             9                 1.14×10^−07^
   hsa04152          AMPK signaling pathway                                                             7                 7.34×10^−04^
   hsa04964          Proximal tubule bicarbonate reclamation                                            4                 0.001072
   hsa04923          Regulation of lipolysis in adipocytes                                              5                 0.001523
   hsa00982          Drug metabolism-cytochrome P450                                                    5                 0.003116
   hsa04920          Adipocytokine signaling pathway                                                    5                 0.003462
   hsa00350          Tyrosine metabolism                                                                4                 0.00367
   hsa00561          Glycerolipid metabolism                                                            4                 0.014956
   hsa00980          Metabolism of xenobiotics by cytochrome P450                                       4                 0.028412
   hsa05205          Proteoglycans in cancer                                                            6                 0.033006

KEGG, Kyoto Encyclopedia of genes and genomes; GO, Gene Ontology.

###### 

Association of *NUF2* with clinical pathological characteristics of breast cancer patients from Shaoxing People\'s Hospital.

  Pathological characteristics   Number of patients (%)   *NUF2* (%)   P-value[a](#tfn2-ijmm-44-02-0390){ref-type="table-fn"}   
  ------------------------------ ------------------------ ------------ -------------------------------------------------------- ------------------------------------------------------
  Age                                                                                                                           0.031
   \<60                          21 (50.0)                14 (66.7)    7 (33.3)                                                 
   ≥60                           21 (50.0)                7 (33.3)     14 (66.7)                                                
  HER2 status                                                                                                                   0.05
   Positive                      14 (33.3)                10 (71.4)    4 (29.6)                                                 
   Negative                      28 (66.7)                11 (39.3)    17 (60.7)                                                
  ER status                                                                                                                     0.679[b](#tfn3-ijmm-44-02-0390){ref-type="table-fn"}
   Positive                      35 (83.3)                17 (48.6)    18 (51.4)                                                
   Negative                      7 (16.7)                 4 (57.1)     3 (42.9)                                                 
  PR status                                                                                                                     0.107
   Positive                      27 (64.3)                11 (40.7)    16 (59.3)                                                
   Negative                      15 (35.7)                10 (66.7)    5 (33.3)                                                 
  TNM stage                                                                                                                     0.751
   1                             12 (28.6)                5 (41.7)     7 (58.3)                                                 
   2                             25 (59.5)                13 (52.0)    12 (48.0)                                                
   3                             5 (11.9)                 3 (60.0)     2 (40.0)                                                 
  Tumor stage                                                                                                                   0.333
   T1                            19 (45.2)                8 (42.1)     11 (57.9)                                                
   T2                            22 (52.4)                13 (59.1)    9 (40.9)                                                 
   T3                            1 (2.4)                  0 (0.0)      1 (100.0)                                                
  Lymph node stage                                                                                                              0.946
   N0                            27 (64.3)                13 (48.1)    14 (51.9)                                                
   N1                            10 (23.8)                5 (50.0)     5 (50.0)                                                 
   N2                            3 (7.1)                  2 (66.7)     1 (33.3)                                                 
   N3                            2 (4.3)                  1 (50.0)     1 (50.0)                                                 
  Node metastasis                                                                                                               0.533
   Yes                           18 (42.9)                10 (55.6)    8 (44.4)                                                 
   No                            24 (57.1)                11 (45.8)    13 (54.2)                                                

Unless otherwise noted, χ^2^ tests were used for comparisons between groups.

χ^2^ test with continuity correction was used. ER, estrogen receptor; PR, progesterone receptor; TNM, tumor node metastasis; NUF2, NDC80 kinetochore complex component.

###### 

Association of *NUF2* with clinical pathological characteristics of breast cancer patients derived from TCGA database.

  Pathological characteristics   Number of patients (%)   *NUF2* (%)   P-value[a](#tfn4-ijmm-44-02-0390){ref-type="table-fn"}   
  ------------------------------ ------------------------ ------------ -------------------------------------------------------- ---------
  Age                                                                                                                           \<0.001
   \<60                          579 (53.2)               255 (44.0)   324 (66.0)                                               
   ≥60                           510 (46.8)               289 (56.7)   221 (43.3)                                               
  HER2 status                                                                                                                   0.296
   Positive                      90 (21.4)                39 (43.3)    51 (56.7)                                                
   Negative                      331 (78.6)               164 (49.5)   167 (50.5)                                               
  ER status                                                                                                                     \<0.001
   Positive                      803 (77.2)               467 (58.2)   336 (41.8)                                               
   Negative                      237 (22.8)               60 (25.3)    177 (74.7)                                               
  PR status                                                                                                                     \<0.001
   Positive                      694 (66.9)               415 (60.0)   279 (40.0)                                               
   Negative                      343 (33.1)               110 (32.1)   233 (67.9)                                               
  Histology type                                                                                                                \<0.001
   IDC                           779 (79.3)               326 (41.8)   453 (58.2)                                               
   ILC                           203 (20.7)               156 (76.8)   47 (23.2)                                                
  TNM stage                                                                                                                     0.032
   1                             181 (17.0)               108 (59.7)   73 (40.3)                                                
   2                             619 (58.0)               293 (47.3)   326 (52.7)                                               
   3                             247 (23.1)               119 (48.2)   128 (51.8)                                               
   4                             20 (1.9)                 10 (50.0)    10 (50.0)                                                
  Tumor stage                                                                                                                   \<0.001
   T1                            279 (25.7)               171 (61.3)   108 (38.7)                                               
   T2                            631 (58.0)               283 (44.8)   348 (55.2)                                               
   T3                            137 (12.6)               71 (51.8)    66 (48.2)                                                
   T4                            40 (3.7)                 19 (47.5)    21 (52.5)                                                
  Lymph node stage                                                                                                              0.095
   N0                            514 (48.0)               255 (49.6)   259 (50.4)                                               
   N1                            360 (33.6)               185 (51.4)   175 (48.6)                                               
   N2                            120 (11.2)               48 (40.0)    72 (60.0)                                                
   N3                            76 (7.2)                 43 (56.6)    33 (43.4)                                                
  Metastasis stage                                                                                                              0.82
   M0                            906 (97.6)               434 (47.9)   472 (52.1)                                               
   M1                            22 (2.4)                 10 (45.5)    12 (54.5)                                                
  Molecular subtype                                                                                                             \<0.001
   Luminal A                     419 (0.5)                305 (72.8)   114 (27.2)                                               
   Luminal B                     190 (0.23)               26 (13.7)    164 (86.3)                                               
   HER2+                         67 (0.08)                26 (38.8)    41 (61.2)                                                
   Basal-like                    139 (0.16)               14 (10.1)    125 (89.9)                                               
   Normal-like                   23 (0.03)                21 (91.3)    2 (8.7)                                                  

χ^2^ tests were used for comparisons between groups. TNM, tumor node metastasis; ER, estrogen receptor; PR, progesterone receptor; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; NUF2, NDC80 kinetochore complex component.

###### 

Comparison of clinical pathological characteristics of breast cancer patients from Shaoxing People\'s Hospital among multiple groups.

  Pathological characteristics   Pairwise comparisons (P-values)                   
  ------------------------------ --------------------------------- ------- ------- -------
  TNM stage                      1                                 2       3       
   1                             N/A                               0.556   0.620   
   2                             0.556                             N/A     1.000   
   3                             0.620                             1.000   N/A     
  Tumor stage                    T1                                T2      T3      
   T1                            N/A                               0.278   1.000   
   T2                            0.278                             N/A     0.435   
   T3                            1.000                             0.435   N/A     
  Lymph node stage               N0                                N1      N2      N3
   N0                            N/A                               1.000   1.000   1.000
   N1                            1.000                             N/A     1.000   1.000
   N2                            1.000                             1.000   N/A     1.000
   N3                            1.000                             1.000   1.000   N/A

P\<0.05/N was considered statistically significant, where N was the number of pairwise comparisons. TNM, tumor node metastasis.

###### 

Comparison of clinical pathological characteristics of breast cancer patients in The Cancer Genome Atlas database among multiple groups.

  Pathological characteristics   Pairwise comparisons (P-values)                                                                                                                                                                                             
  ------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  TNM stage                      1                                                      2                                                      3                                                      4                                                      
   1                             N/A                                                    0.004[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.019                                                  0.405                                                  
   2                             0.004[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.822                                                  0.814                                                  
   3                             0.019                                                  0.822                                                  N/A                                                    0.875                                                  
   4                             0.405                                                  0.814                                                  0.875                                                  N/A                                                    
  Tumor stage                    T1                                                     T2                                                     T3                                                     T4                                                     
   T1                            N/A                                                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.066                                                  0.097                                                  
   T2                            0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.138                                                  0.744                                                  
   T3                            0.066                                                  0.138                                                  N/A                                                    0.630                                                  
   T4                            0.097                                                  0.744                                                  0.630                                                  N/A                                                    
  Lymph node stage               N0                                                     N1                                                     N2                                                     N3                                                     
   N0                            N/A                                                    0.605                                                  0.058                                                  0.257                                                  
   N1                            0.605                                                  N/A                                                    0.031                                                  0.410                                                  
   N2                            0.058                                                  0.031                                                  N/A                                                    0.023                                                  
   N3                            0.257                                                  0.410                                                  0.023                                                  N/A                                                    
  Molecular subtype              Luminal A                                              Luminal B                                              HER2+                                                  Basal-like                                             Normal-like
   Luminal A                     N/A                                                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.049
   Luminal B                     0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.322                                                  0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}
   HER2+                         0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}
   Basal-like                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.322                                                  0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}
   Normal-like                   0.049                                                  0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn7-ijmm-44-02-0390){ref-type="table-fn"}   N/A

P\<0.05/N was considered statistically significant, where N was the number of pairwise comparisons.

P\<0.05/N. TNM, tumor, node and metastasis.

###### 

Comparison of Kaplan-Meier curves among multiple groups.

  Datasets               Pairwise comparisons (P-values)                                                                                                                                                                        
  ---------------------- --------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  GSE1456 OS             Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.088                                                  0.008[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.003[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.088                                                  N/A                                                    0.356                                                  0.253
                         X3                                0.008[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.356                                                  N/A                                                    0.851
                         X4                                0.003[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.253                                                  0.851                                                  N/A
  GSE1456 PFS            Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.259                                                  0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.004[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.259                                                  N/A                                                    0.044                                                  0.068
                         X3                                0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.044                                                  N/A                                                    0.800
                         X4                                0.004[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.068                                                  0.800                                                  N/A
  NKI OS                 Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.036                                                  0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.036                                                  N/A                                                    0.113                                                  0.041
                         X3                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.113                                                  N/A                                                    0.663
                         X4                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.041                                                  0.663                                                  N/A
  NKI PFS                Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.361                                                  0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.003[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.361                                                  N/A                                                    0.034                                                  0.057
                         X3                                0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.034                                                  N/A                                                    0.840
                         X4                                0.003[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.057                                                  0.840                                                  N/A
  GEO pooled OS          Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.007[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.007[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.063                                                  0.017
                         X3                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.063                                                  N/A                                                    0.630
                         X4                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.017                                                  0.630                                                  N/A
  GEO pooled PFS         Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.027                                                  0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.027                                                  N/A                                                    0.010                                                  0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X3                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.010                                                  N/A                                                    0.639
                         X4                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.002[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.639                                                  N/A
  GEO pooled ER(+) OS    Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.006[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.006[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   N/A                                                    0.307                                                  0.314
                         X3                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.307                                                  N/A                                                    0.925
                         X4                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.314                                                  0.925                                                  N/A
  GEO pooled ER(+) PFS   Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.197                                                  0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.001[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}
                         X2                                0.197                                                  N/A                                                    0.022                                                  0.065
                         X3                                0.000[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.022                                                  N/A                                                    0.730
                         X4                                0.001[a](#tfn9-ijmm-44-02-0390){ref-type="table-fn"}   0.065                                                  0.730                                                  N/A
  GEO pooled ER(−) OS    Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.495                                                  0.031                                                  0.016
                         X2                                0.495                                                  N/A                                                    0.079                                                  0.028
                         X3                                0.031                                                  0.079                                                  N/A                                                    0.762
                         X4                                0.016                                                  0.028                                                  0.762                                                  N/A
  GEO pooled ER(−) PFS   Subsets                           X1                                                     X2                                                     X3                                                     X4
                         X1                                N/A                                                    0.679                                                  0.029                                                  0.055
                         X2                                0.679                                                  N/A                                                    0.095                                                  0.106
                         X3                                0.029                                                  0.095                                                  N/A                                                    0.834
                         X4                                0.055                                                  0.106                                                  0.834                                                  N/A

P\<0.05/N was considered statistically significant, where N was the number of pairwise comparisons.

P\<0.05/N. OS, overall survival; PFS, progression-free survival; ER, estrogen receptor.

###### 

Univariate and multivariate analyses of NUF2 and survival in GEO datasets.

  Dataset            Overall survival                                                    Progression-free survival                                                                                                               
  ------------------ ------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  GSE1456                                                                                                                                                                                                                        
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                3.94 (0.82-18.95)                                                   3.66 (0.75-17.75)                                                   2.19 (0.55-8.74)                                                    1.99 (0.49-8.05)
   X3                6.18 (1.37-27.90)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}   4.6 (0.91-23.28)                                                    5.7 (1.64-19.83)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    3.94 (1.00-15.45)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
   X4                6.69 (1.50-29.91)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}   5.11 (1.03-25.24)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}   5.21 (1.48-18.29)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}   3.76 (0.97-14.57)
  GSE22220                                                                                                                                                                                                                       
   X1                N/A                                                                 N/A                                                                 Reference                                                           Reference
   X2                N/A                                                                 N/A                                                                 2.05 (0.95-4.43)                                                    1.69 (0.77-3.69)
   X3                N/A                                                                 N/A                                                                 2.31 (1.07-4.96)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.79 (0.82-3.92)
   X4                N/A                                                                 N/A                                                                 3.34 (1.60-6.95)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.30 (1.05-5.02)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
  NKI dataset                                                                                                                                                                                                                    
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                2.39 (1.04-5.51)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    2.01 (0.87-4.68)                                                    1.35 (0.72-2.54)                                                    1.29 (0.68-2.46)
   X3                3.97 (1.80-8.77)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.88 (1.28-6.48)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    2.39 (1.33-4.30)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    1.97 (1.07-3.61)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
   X4                4.48 (2.03-9.89)[c](#tfn13-ijmm-44-02-0390){ref-type="table-fn"}    2.63 (1.13-6.12)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    2.31 (1.27-4.21)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    1.84 (0.96-3.52)
  GSE4299                                                                                                                                                                                                                        
   X1                N/A                                                                 N/A                                                                 Reference                                                           Reference
   X2                N/A                                                                 N/A                                                                 1.95 (0.99-3.85)                                                    1.93 (0.97-3.81)
   X3                N/A                                                                 N/A                                                                 2.16 (1.09-4.27)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    2.13 (1.07-4.24)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
   X4                N/A                                                                 N/A                                                                 2.11 (1.07-4.17)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    2.09 (1.04-4.19)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
  GSE20685                                                                                                                                                                                                                       
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                1.11 (0.57-2.14)                                                    1.1 (0.57-2.14)                                                     1.17 (0.67-2.05)                                                    1.16 (0.66-2.03)
   X3                1.58 (0.85-2.95)                                                    1.58 (0.85-2.95)                                                    1.12 (0.64-1.98)                                                    1.13 (0.64-2.00)
   X4                1.59 (0.85-2.96)                                                    1.58 (0.84-2.97)                                                    1.46 (0.84-2.52)                                                    1.42 (0.82-2.48)
  GEO pooled                                                                                                                                                                                                                     
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                2.69 (1.29-5.60)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.18 (1.04-4.57)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.67 (1.05-2.65)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.5 (0.95-2.39)
   X3                4.43 (2.20-8.91)[c](#tfn13-ijmm-44-02-0390){ref-type="table-fn"}    3 (1.46-6.15)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}       2.72 (1.77-4.19)[c](#tfn13-ijmm-44-02-0390){ref-type="table-fn"}    2.13 (1.36-3.32)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}
   X4                4.94 (2.46-9.92)[c](#tfn13-ijmm-44-02-0390){ref-type="table-fn"}    2.87 (1.38-5.94)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.98 (1.94-4.59)[c](#tfn13-ijmm-44-02-0390){ref-type="table-fn"}    2.1 (1.33-3.32)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}
  GEO pooled ER(+)                                                                                                                                                                                                               
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                3.84 (1.41-10.48)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}   3.23 (1.18-8.88)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.57 (0.79-3.13)                                                    1.39 (0.70-2.79)
   X3                5.48 (2.08-14.49)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}   3.93 (1.46-10.61)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}   3.03 (1.62-5.69)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.32 (1.22-4.44)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
   X4                5.60 (2.06-15.23)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}   3.74 (1.34-10.46)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}   2.83 (1.45-5.52)[b](#tfn12-ijmm-44-02-0390){ref-type="table-fn"}    2.09 (1.04-4.16)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}
  GEO pooled ER(−)                                                                                                                                                                                                               
   X1                Reference                                                           Reference                                                           Reference                                                           Reference
   X2                1.40 (0.46-4.20)                                                    1.19 (0.39-3.61)                                                    1.28 (0.46-3.62)                                                    1.09 (0.38-3.11)
   X3                2.96 (1.07-8.20)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.88 (0.65-5.45)                                                    2.60 (1.01-6.72)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.58 (0.58-4.34)
   X4                3.23 (1.22-8.54)[a](#tfn11-ijmm-44-02-0390){ref-type="table-fn"}    1.96 (0.70-5.52)                                                    2.44 (0.97-6.10)                                                    1.46 (0.54-3.91)

For multivariate analysis, HR was adjusted by ER status and Elston grade in GSE1456. In GSE22220, HR was adjusted by age and Elston grade. In NKI and GSE4299, HR was adjusted by age, Elston grade, and ER status. For GSE20685, HR was adjusted by age. HR was adjusted by ER status and Elston grade in the pooled analysis. For GEO pooled ER(+) and GEO pooled ER(−), HR was adjusted by Elston grade.

P\<0.05,

P\<0.01 and

P\<0.001 vs. the X1 group. HR, hazard ratio; ER, estrogen receptor; GEO, gene expression omnibus; CI, confidence interval.
